Skip to main content Accessibility help
×
Home

Visual Defects Associated with Vigabatrin: A Study of Epileptic Argentine Patients

  • María Cecilia Moreno (a1), Brenda Giagante (a2), Patricia Saidon (a2), Silvia Kochen (a2), Jorge Benozzi (a1) and Ruth E. Rosenstein (a1)...

Abstract:

Objective:

The aim of the present study was to assess visual alterations in a population of Argentine patients treated with the antiepileptic drug vigabatrin.

Methods:

Twenty patients receiving vigabatrin and 15 patients receiving carbamazepine were examined with automated perimetry using a Humphrey 120-point full screening strategy. In addition, scotopic flash electroretinograms were performed.

Results:

Of 20 patients treated with vigabatrin, two were unable to cooperate with testing. Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40° of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin.

Conclusions:

Visual field defects among patients on vigabatrin therapy may occur with a higher frequency than previously recognized. The Humphrey 120-points full field screening test and electroretinography are useful tools to assess the visual dysfunction associated with vigabatrin.

RÉSUMÉ: Objectif:

Le but de cette étude était d’évaluer les changements visuels chez un groupe de patients argentins traités par le vigabatrin, un médicament anti-épileptique.

Méthodes:

Vingt patients recevant du vigabatrin et 15 patients recevant de la carbamazépine ont subi une périmétrie de dépistage plein écran de 120 points au moyen de l’appareil automatisé Humphrey. De plus, des électrorétinogrammes au flash scotopique ont été effectués.

Résultats:

L’étude n’a pu être réalisée chez deux des 20 patients traités par le vigabatrin à cause de leur manque de coopération. Chez les 18 autres patients, tous sauf deux avaient au moins un point non détecté au champ visuel central de 40o de chaque oeil. Trois des 15 patients recevant de la carbamazépine n’ont pu compléter l’étude. Aucun des 12 autres patients n’avait de déficit au niveau des champs visuels. L’amplitude des ondes a et b de l’électrorétinogramme scotopique était significativement diminuée chez 12 patients recevant le vigabatrin.

Conclusions:

Des anomalies du champ visuel sont peut-être plus fréquentes qu’on ne l’estimait chez les patients recevant du vigabatrin. La périmétrie automatisée Humphrey plein écran de 120 points et l’électrorétinographie sont des méthodes utiles pour évaluer la dysfonction visuelle associée au vigabatrin.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Visual Defects Associated with Vigabatrin: A Study of Epileptic Argentine Patients
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Visual Defects Associated with Vigabatrin: A Study of Epileptic Argentine Patients
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Visual Defects Associated with Vigabatrin: A Study of Epileptic Argentine Patients
      Available formats
      ×

Copyright

Corresponding author

Departamento de Bioquímica Humana, Facultad de Medicina, UBA, Paraguay 2155, 5º P, (1121), Buenos Aires, Argentina

References

Hide All
1. Eke, T, Talbot, JF, Lawden, MC. Severe persistent visual fieldconstriction associated with vigabatrin. BMJ 1997; 314: 180181.
2. Harding, GF, Robertson, KA, Edson, AS, et al. Visualelectrophysiological effect of a GABA transaminase blocker. Doc Ophthalmol 1998; 97: 179188.
3. Kalviainen, R, Nousiainen, I, Mantyjarvi, , et al. Vigabatrin, aGABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922926.
4. Toggweiler, S, Wieser, HG. Concentric visual field restriction undervigabatrin therapy: extent depends on the duration of drug intake. Seizure 2001; 10: 420423.
5. Mauri-Llerda, JA, Iniguez, C, Tejero-Juste, C, et al. Visual fieldchanges secondary to vigabatrin treatment. Rev Neurol 2000; 31: 11041108.
6. Martinez, C, Noack, H. The risk of visual field defects and the use ofvigabatrin. Denham: Hoechst Marion Roussel, 1997. (Internal report.)
7. Lawden, MC, Eke, T, Degg, C, et al. Visual field defects associatedwith vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67: 716722.
8. Miller, NR, Johnson, MA, Paul, SR, et al. Visual dysfunction inpatients receiving vigabatrin: clinical and electrophysiologicfindings. Neurology 1999; 53: 20822087.
9. Midelfart, A, Midelfart, E, Brodtkorb, E. Visual field defects inpatients taking vigabatrin. Acta Ophthalmol Scand 2000; 78: 580584.
10. Krauss, GL, Johnson, MA, Miller, NR. Vigabatrin-associated retinalcone system dysfunction: electroretinogram and ophthalmologicfindings. Neurology 1998; 50: 614618.
11. Harding, GF, Wild, JM, Robertson, KA, et al. Separating the retinalelectrophysiologic effects of vigabatrin: treatment versus fieldloss. Neurology 2000; 55: 347352.
12. Johnson, MA, Krauss, GL, Miller, NR, et al. Visual function loss fromvigabatrin: effect of stopping the drug. Neurology 2000; 55: 4045.
13. Daneshvar, H, Racette, L, Coupland, SG, et al. Symptomatic andasymptomaticvisual lossinpatientstaking vigabatrin. Ophthalmology 1999; 106: 17921798.
14. Comaish, IF, Gorman, C, Brimlow, GM, et al. The effects ofvigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol. 2002; 104: 195212.
15. Mosinger, JL, Yazulla, S, Studholme, KM. GABA-likeimmunoreactivity in the vertebrate retina: a species comparison. Exp Eye Res 1986; 42: 631644.
16. Lopez-Costa, JJ, Goldstein, J, Pecci-Saavedra, J, et al. GABA releasemechanism in the golden hamster retina. Int J Neurosci 1999; 98: 1325.
17. Frumkes, TE, Nelson, R. Functional role of GABA in cat retina: I. Effects of GABAA agonists Vis Neurosci 1995; 12: 641650.
18. Butler, WH, Ford, GP, Newberne, JW. A study of the effects ofvigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol 1987; 15: 143148.
19. Gottlob, I, Wundsch, L, Tuppy, FK. The rabbit electroretinogram:effect of GABA and its antagonists. Vision Res 1988; 28: 203210.
20. Sills, GJ, Patsalos, PN, Butler, E, et al. Visual field constriction:Accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001; 57: 196200.
21. Neal, MJ, Shah, MA. Development of tolerance to the effects ofvigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina. Br J Pharmacol 1990; 100: 324328.
22. Coupland, SG, Zackon, DH, Leonard, BC, Ross, TM. Vigabatrin effecton inner retinal function. Ophthalmology 2001; 108: 14931496.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed